Please login to the form below
baricitinib
This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.
New data keeps AbbVie’s star pipeline therapies on track
Lilly reported positive phase II results with its already-approved Olumiant (baricitinib) drug in the skin disorder at last year’s EADV, as did Pfizer with PF-04965842, a more selective
Latest news
-
Gilead, Galapagos JAK inhibitor clears phase II test
DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in
-
GSK sells eczema and psoriasis drug to Dermavant for £250m
s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.
-
Another R&D flop for Incyte, but Jakafi keeps delivering
Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)
-
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
be an under-estimate given that a third JAK inhibitor - Eli Lilly and Incyre’s Olumiant (baricitinib) - has been dogged by regulatory problems.
-
FDA panel undermines Lilly and Incyte’s baricitinib hopes
FDA panel undermines Lilly and Incyte’ s baricitinib hopes. Mixed review doesn’t bode well in competitive market. ... baricitinib’s potential to cause side effects such as pulmonary embolism and venous thromboembolism.
More from news
Approximately 10 fully matching, plus 27 partially matching documents found.
Featured jobs
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Sudler London - Account Director
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Medical Writers Required - Hertfordshire
-
Competitive
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Sudler London - Senior Medical Writer
-
Competitive
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
Subscribe to our email news alerts
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Innovate UK supports AI drug discovery project worth £1m
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Superhuman editor wins promotion at Porterhouse Medical
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
